Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 6, 2023Antimicrobial Agents and ChemotherapyOpen Access

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JVJosé A. VázquezPPPeter G. PappasKBKenneth D Boffard

Discussion

Loading...

Member takes

Overview

Phase 2 single-arm trial reports safety and efficacy of fosmanogepix in Candida auris candidemia, highlighting a novel treatment for drug-resistant fungal infections.

Key Points

  • To assess the clinical safety and efficacy of intravenous and oral fosmanogepix for treating candidemia and invasive candidiasis caused by Candida auris.
  • Multicenter, open-label, single-arm phase 2 interventional clinical trial.
  • Administered intravenous and oral formulations of the novel antifungal fosmanogepix to patients with Candida auris candidemia or invasive candidiasis.
  • Quantitative clinical efficacy endpoints, primary response rates, and safety outcomes were not provided in the abstract text.
  • Fosmanogepix demonstrates broad-spectrum activity against pathogenic yeasts and molds, including fungal strains resistant to standard-of-care agents.

Cite This Study

Vázquez et al. (2023) studied this question.

synapsesocial.com/papers/6aa53b2c04ea443b843a497ahttps://doi.org/10.1128/aac.01419-22
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Perspectives on Antimicrobial Agents: Fosmanogepix2026
  2. 2Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials2024 · 22 citations
  3. 3Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants2024 · 10 citations
  4. 4Use of Expanded Access Fosmanogepix in Two Pediatric Patients With Rhino‐Orbital‐Cerebral Mucormycosis2026
  5. 5Fosmanogepix treatment for coccidioidomycosis under an expanded access program2026 · 2 citations